Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Clinical trial NCT05611853 · TERMINATED

Trial details

NCT number: NCT05611853
Sponsor: BioNova Pharmaceuticals (Shanghai) LTD.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B-cell Lymphoma Non Hodgkin Lymphoma Diffuse Large B Cell Lymphoma Follicular Lymphoma Mantle Cell Lymphoma

Start date: 2022-11-25
Primary completion: 2023-12-25
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.